2019 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

February 2019 | 87 pages | ID: 26C0D95B187EN
VPAResearch

Abstracts

The ongoing clinical trial research report- “2019 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials Study” analyzes the current scenario of all active Methicillin-Resistant Staphylococcus aureus (MRSA) Infections trials across the world. The report presents top level analysis of global Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials by-

• Region (Asia Pacific, Europe, Middle East Africa and Americas)
• Countries
• Trial Phase
• Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)
• Type of the trial (Interventional, Observational)
• Sponsor Type (Companies, Universities, Government Bodies etc)
• Enrollment across types, sponsor types, geographies, current status and phases

The report also identifies the potential drug candidates under development for treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections on the basis of intervention type ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections trials.

The research work is prepared through extensive and continuous research on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

REPORT SCOPE AND COVERAGE:

• All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Methicillin-Resistant Staphylococcus aureus (MRSA) Infections patients are identified
• The report includes panorama of ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials Overview, 2019
2.2 Premium Insights into Ongoing Clinical Trials
  2.2.1 Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Region
  2.2.2 Average Enrollment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials
  2.2.3 Companies participating in Ongoing Trials
  2.2.4 Drugs under Study for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Treatment, 2019

3. REGION WISE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS CLINICAL TRIALS

3.1 Asia Pacific Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country
3.2 Europe Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country
3.3 North America Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country
3.4 Middle East and Africa Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country
3.5 South and Central America Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country

4. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials
4.2 Phase wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials
4.3 Trial Status wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials
4.4 Trial Type wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials

5. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Year
5.2 Average Enrollment in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Phase
5.3 Average Enrollment in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Status
5.4 Average Enrollment in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ONGOING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS CLINICAL TRIALS

6.1 Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Sponsor Type
6.2 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials- Phase
7.2 Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials- Phase
7.3 Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials- Phase
7.4 Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 5: Europe – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 7: North America – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 9: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials by Phase
Figure 10: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials by Trial Status
Figure 11: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials by Type
Figure 12: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials by Sponsor Type
Figure 13: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials by Leading Sponsors
Figure 14: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Phase
Figure 15: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Trial Status
Figure 16: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Type
Figure 17: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections- Average Enrolment by Type of Sponsors
Figure 18: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Ongoing Clinical Trials Snapshot- 2019
Table 2: Ongoing Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 5: Europe – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 7: North America – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Ongoing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Phase
Table 15: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Trial Status
Table 16: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Type
Table 17: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections- Average Enrolment by Type of Sponsors
Table 18: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections- Enrolment by Leading Sponsors